NK-/T-cell lymphomas

Wang, Hua; Fu, Bibo; Gale, Robert Peter; Liang, Yang

doi:10.1038/s41375-021-01313-2

Cited by 90 publications

(72 citation statements)

References 125 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We will not discuss these in details, but excellent reviews, such as those from Nebrinsky and co-workers, Chung et al, Klener and Klanova, or Othman and co-workers are suggested in this topic for those interested [370,381,384,385]. In addition, therapeutic challenges for NK/T-cell lymphomas are discussed in articles, such as the ones from Xue and Zhang, or Wang and co-workers [386,387]. nHLs and mitochondria.…”

Section: Non-hodgkin Lymphomas (Nhls)mentioning

confidence: 99%

Mitochondria and Their Relationship with Common Genetic Abnormalities in Hematologic Malignancies

Czegle

Gray

Wang³

et al. 2021

Life

View full text Add to dashboard Cite

Hematologic malignancies are known to be associated with numerous cytogenetic and molecular genetic changes. In addition to morphology, immunophenotype, cytochemistry and clinical characteristics, these genetic alterations are typically required to diagnose myeloid, lymphoid, and plasma cell neoplasms. According to the current World Health Organization (WHO) Classification of Tumors of Hematopoietic and Lymphoid Tissues, numerous genetic changes are highlighted, often defining a distinct subtype of a disease, or providing prognostic information. This review highlights how these molecular changes can alter mitochondrial bioenergetics, cell death pathways, mitochondrial dynamics and potentially be related to mitochondrial genetic changes. A better understanding of these processes emphasizes potential novel therapies.

show abstract

Section: Non-hodgkin Lymphomas (Nhls)mentioning

confidence: 99%

Mitochondria and Their Relationship with Common Genetic Abnormalities in Hematologic Malignancies

Czegle

Gray

Wang³

et al. 2021

Life

View full text Add to dashboard Cite

show abstract

“…ENKTL is a tumor of either NK cell or cytotoxic T cell lineage. T and NK cells originate from the same lymphoid progenitor cells and develop into different cell lineages with the rearrangement of TCR gene [40]. Because T and NK cells share the expression of some T and NK cell markers, the cell lineage cannot be distinguished only by immunophenotype; instead, it is determined by either the TCR gene rearrangement or the expression of the TCR antigen.…”

Section: Cell Of Originmentioning

confidence: 99%

The Pathologic and Genetic Characteristics of Extranodal NK/T-Cell Lymphoma

Kim

2022

Life

View full text Add to dashboard Cite

Extranodal NK/T-cell lymphoma is a neoplasm of NK cells or cytotoxic T cells presenting in extranodal sites, most often in the nasal cavity. The typical immunophenotypes are cCD3+, sCD3−, CD4−, CD5−, CD8−, CD16−, and CD56+ with the expression of cytotoxic molecules. Tumor subsets express NK cell receptors, CD95/CD95L, CD30, MYC, and PDL1. Virtually all the tumor cells harbor the EBV genome, which plays a key role in lymphomagenesis as an epigenetic driver. EBV-encoded oncoproteins modulate the host-cell epigenetic machinery, reprogramming the viral and host epigenomes using host epigenetic modifiers. NGS analysis revealed the mutational landscape of ENKTL, predominantly involving the JAK–STAT pathway, epigenetic modifications, the RNA helicase family, the RAS/MAP kinase pathway, and tumor suppressors, which indicate an important role of these pathways and this group of genes in the lymphomagenesis of ENKTL. Recently, three molecular subtypes were proposed, the tumor-suppressor/immune-modulator (TSIM), MGA-BRDT (MB), and HDAC9-EP300-ARID1A (HEA) subtypes, and they are well-correlated with the cell of origin, EBV pattern, genomic alterations, and clinical outcomes. A future investigation into the function and interaction of discovered genes would be very helpful for better understanding the molecular pathogenesis of ENKTL and establishing better treatment strategies.

show abstract

“…Extranodal NK/T-cell lymphoma (ENKTL) is a highly aggressive lymphoma that has a geographic predilection in Asian and South American populations (1)(2)(3)(4). In China, the incidence of ENKTL is higher and secondary to the diffuse large B-cell lymphoma, accounting for approximately 11% of all lymphomas (5).…”

Section: Introductionmentioning

confidence: 99%

Phase II Study of Gemcitabine, Peg-Asparaginase, Dexamethasone and Methotrexate Regimen for Newly Diagnosed Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: Final Analysis With Long-Term Follow-Up and Rational Research for the Combination

Wang

Sun

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Patients with extranodal natural killer/T-cell lymphoma (ENKTL), nasal type are benefit from peg-asparaginase, gemcitabine, and methotrexate. Therefore, we conducted a prospective phase II trial using a combination of these drugs as GAD-M regimen in naïve ENKTL patients, simultaneously, explored the combinational mechanism. The GAD-M regimen was administered for 6 cycles sandwiched by radiotherapy for stage I/II and 6 cycles for stage III/IV patients. After 6 cycles, the overall response rate of 36 patients was 91.6%, and the complete remission rate increased to 83.3%. The 3-year progression-free survival (PFS) and overall survival (OS) rates were 74.8% and 77.8%, respectively. The 5-year PFS and OS were 68.3% and 77.8%. No patient suffered from the central nervous system (CNS) relapse. Most patients experienced recoverable liver dysfunction and anemia in this study. The plasma MTX concentration ratio at 12 to 24 hr during the first cycle could be an early predictor of outcomes in ENKTL (PFS, P=0.005; OS, P=0.002). Additionally, we found that high dose MTX (HD-MTX) and gemcitabine had the synergistic effect of ENKTL cell in vitro. Mechanistically, we demonstrated that the combination could lead to obviously apoptosis in ENKTL cell with extremely release of reactive oxygen spices (ROS), which mediated by endoplasmic reticulum stress. In conclusion, the GAD-M regimen could be a new choice to newly diagnosed ENKTL, especially for stage I/II patients. Furthermore, our results showed the synergy effect of HD-MTX with gemcitabine in ENKTL.Clinical Trial RegistrationThis trial was registered at www.clinicaltrials.gov as #NCT01991158.

show abstract

NK-/T-cell lymphomas

Cited by 90 publications

References 125 publications

Mitochondria and Their Relationship with Common Genetic Abnormalities in Hematologic Malignancies

Mitochondria and Their Relationship with Common Genetic Abnormalities in Hematologic Malignancies

The Pathologic and Genetic Characteristics of Extranodal NK/T-Cell Lymphoma

Phase II Study of Gemcitabine, Peg-Asparaginase, Dexamethasone and Methotrexate Regimen for Newly Diagnosed Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type: Final Analysis With Long-Term Follow-Up and Rational Research for the Combination

Contact Info

Product

Resources

About